SIRT2 and cancer: The PROteasome TArgeting Chimera (PROTAC), a recently introduced technology, can overcome some of the limitations, since it degrades proteins in a spatiotemporal manner [135,136], as we have hijacked SIRT2 as a potential anti-cancer drug target [137].